Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1
Is Low-frequency Repetitive Nerve Stimulation a Reliable Test to Evaluate the Neuromuscular Junction in Myotonic Dystrophy Type 1
The study design is a prospective cohort study. It aims to evaluate the neuromuscular junction in dystrophic myotonia 1 (DM 1) using low-frequency repetitive nerve stimulation (RNS) on several nerve-muscle pairs of the one side including proximal and distal muscles of upper and lower extremities. First, it will be investigated whether a decrement with 3 Hz stimulation, as described in literature, is reproducible in our patient population. If this is the case, it will be examined whether it is the consequence of a dysfunction of the neuromuscular junction or rather linked to a hypo-excitability of some muscle fibers due to myotonia. For this purpose, additional tests including short exercise test (to observe any decrement resulting from an inexcitability in myotonic muscle fibers) and needle EMG (for mapping myotonic discharges in the muscles tested with repetitive nerve stimulation) will be performed. Single fiber-EMG will not be provided in this study as an abnormal result does not necessarily indicate a dysfunction of the neuromuscular junction but could just as well be due to the muscular dystrophy in the context of DM1. Finally, it will be investigated if there is a correlation between the decrement
with 3 Hz stimulation and clinical signs as fixed muscle weakness (via Medical Research Counsil (MRC) scale, DM-activ scale [30]) and fatigue (via MG-ADL scale).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Brussels Hoofdstedelijk Gewest
-
Jette, Brussels Hoofdstedelijk Gewest, Belgium, 1000
- UZ Brussel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
* genetically confirmed DM1
Exclusion Criteria:
- minor age
- auto-immune diseases
- medical conditions involving the neuromuscular junction: (myasthenia gravis, Lambert-Eaton myasthenic syndrome, congenital myasthenia syndromes).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Questionnaires
Patients with DM1 were asked to complete a questionnaire to rate a 25-item activity scale (DM1-Activ) and the Myasthenia Gravis Activity of Daily Life scale (MG-ADL) to rate their level of functional burden.
For the DM1-Activ a score of 40 alludes no impairment and a score of 0 indicates the highest functional burden of physical activity.
This scale has proven to be practical, reliable and valid.
For the MG-ADL the total score ranges from 0 to 24, a score of 0 denotes no and 24 the highest functional burden.
It should be noted that this scale is not adjusted for DM1.
The rationale was to gain information about muscle fatigue and consequently the neuromuscular junction.
|
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz).
The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
|
|
Active Comparator: grip strength via dynamometer
The isometric grip strength was tested by using a dynamometer.
The subject will be asked to perform an increasing force against the dynamometer over a period of several seconds.
|
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz).
The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
|
|
Active Comparator: short exercise test
The subject was asked to contract the ADM muscle as hard as possible in isometric conditions for 10 seconds.
CMAP's was recorded 2 seconds after the end of the exercise and then every 10 seconds for 50 seconds.
|
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz).
The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
|
|
Active Comparator: needle EMG
The electrical myotonia of each examined muscle was scored according to the Streiss and Sun scale.
|
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz).
The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reproducibility of rapid decrement at low frequency stimulation.
Time Frame: 1 year
|
Low stimulation frequency was tested in 6 muscles, to verify the presence of an anomalie of the neuromuscular transmission.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of decrement with grade of EMG-myotonia
Time Frame: 1 year
|
Search of correlation between decrement, obtained bij low frequency stimulation, and EMG-myotonia (via needle EMG), to differentiate muscle fiber hypoexcitability in the context of myotonia, from neuromuscular junction block resulting in decrement of the CMA
|
1 year
|
|
Is there any clinical expression (muscle fatigability) of a possible neuromuscular junction dysfunction
Time Frame: 1 year
|
Search of correlation between muscle fatique (questionnaires and grip strength via dynamometer) and decrement of CMAP (compound muscle action potential).
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jella De Ville, MD, Universitair Ziekenhuis Brussel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Steinert study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.